

Barcelona, July 23, 2020

In accordance with the Article 525 of the Law on Corporations, **LABORATORIO REIG JOFRE, S.A.** (“Reig Jofre” or “the Company”) informs that the Ordinary and Extraordinary General Meeting of Shareholders, which was held on the first and only call on 23 July 2020 with the established agenda and with the concurrence of shareholders present, who together held 82.085% of the shares representing the share capital.

All the resolutions were approved by a sufficient majority of the share capital, the details of which are as follows

1. Annual Statements and Corporate Management:

a. **Review and approval, where applicable, of the Company’s Individual Financial Statements for the 2019 financial year, duly reviewed by the Company’s auditors**

	Shares	% Share Capital	% Share Capital present and/or represented
Affirmative	62.001.593	81,51405495617900%	99,304287233922600%
Against	0	0,00000000000000%	0,00000000000000%
Abstention	1.050	0,00138044449445%	0,001681722945338%
Blank	0	0,00000000000000%	0,00000000000000%

b. **Review and approval, where applicable, of the Company’s Individual Management Report for the 2019 financial year, duly reviewed by the Company’s auditors**

	Shares	% Share Capital	% Share Capital present and/or represented
Affirmative	62.001.593	81,51405495617900%	99,304287233922600%
Against	0	0,00000000000000%	0,00000000000000%
Abstention	1.050	0,00138044449445%	0,001681722945338%
Blank	0	0,00000000000000%	0,00000000000000%

- c. **Review and approval, where applicable, of the Consolidated Financial Statements corresponding to 2019 of the Company and its subsidiaries, duly reviewed by the Company’s auditors.**

	Shares	% Share Capital	% Share Capital present and/or represented
Affirmative	62.001.593	81,51405495617900%	99,304287233922600%
Against	0	0,00000000000000%	0,00000000000000%
Abstention	1.050	0,00138044449445%	0,001681722945338%
Blank	0	0,00000000000000%	0,00000000000000%

- d. **Review and approval, where applicable, of the consolidated management report corresponding to 2019 of the Company and its subsidiaries, duly reviewed by the Company’s auditors.**

	Shares	% Share Capital	% Share Capital present and/or represented
Affirmative	62.001.593	81,51405495617900%	99,304287233922600%
Against	0	0,00000000000000%	0,00000000000000%
Abstention	1.050	0,00138044449445%	0,001681722945338%
Blank	0	0,00000000000000%	0,00000000000000%

- e. **Review and approval, where applicable, of the consolidate non-financial information statement for 2019.**

	Shares	% Share Capital	% Share Capital present and/or represented
Affirmative	62.001.593	81,51405495617900%	99,304287233922600%
Against	0	0,00000000000000%	0,00000000000000%
Abstention	1.050	0,00138044449445%	0,001681722945338%
Blank	0	0,00000000000000%	0,00000000000000%

f. **Review and approval, where applicable, of the propose appropriation of the profit corresponding to the 2019 financial year, the detail of which as follows**

<u>Basis of distribution</u>	
Profit for the year	<u>2.825.390,38.-€</u>
<u>Distribution</u>	
Legal reserve	282.539,04.-€
Other reserves (voluntary)	<u>2.542.851,34.-€</u>
	<u>2.825.390,38.-€</u>

	Shares	% Share Capital	% Share Capital present and/or represented
Affirmative	62.001.593	81,51405495617900%	99,304287233922600%
Against	0	0,00000000000000%	0,00000000000000%
Abstention	1.050	0,00138044449445%	0,001681722945338%
Blank	0	0,00000000000000%	0,00000000000000%

g. **Approval, where applicable, of the Corporate management during the 2019 financial year.**

	Shares	% Share Capital	% Share Capital present and/or represented
Affirmative	62.001.593	81,51405495617900%	99,304287233922600%
Against	0	0,00000000000000%	0,00000000000000%
Abstention	1.050	0,00138044449445%	0,001681722945338%
Blank	0	0,00000000000000%	0,00000000000000%

2. **Appointment of the new member of the company's Board Directors.**

	Shares	% Share Capital	% Share Capital present and/or represented
Affirmative	62.001.076	81,51337525160410%	99,303459185577100%
Against	0	0,00000000000000%	0,00000000000000%
Abstention	1.567	0,00206014906934%	0,002509771290805%
Blank	0	0,00000000000000%	0,00000000000000%

3. **Appointment, where applicable, of the Auditors of the Company and its consolidated group for the next three years (2020, 2021 y 2022).**

	Shares	% Share Capital	% Share Capital present and/or represented
Affirmative	62.001.593	81,51405495617900%	99,304287233922600%
Against	0	0,00000000000000%	0,00000000000000%
Abstention	1.050	0,00138044449445%	0,001681722945338%
Blank	0	0,00000000000000%	0,00000000000000%

4. **Submission to vote, in a consultative capacity, of the Annual Report on the Remuneration of the Directors of the Company corresponding to 2019.**

	Shares	% Share Capital	% Share Capital present and/or represented
Affirmative	62.006.714	81,52078758118480%	99,312489236973100%
Against	0	0,00000000000000%	0,00000000000000%
Abstention	1.050	0,00138044449445%	0,001681722945338%
Blank	0	0,00000000000000%	0,00000000000000%

5. **Report to the General Shareholders Meeting on the amendment approved by the Board of Directors to the Board of Directors Regulation and reported by de Audit, Compliance and Conflict of interest Committee.**

	Shares	% Share Capital	% Share Capital present and/or represented
Affirmative	62.001.593	81,51405495617900%	99,304287233922600%
Against	0	0,00000000000000%	0,00000000000000%
Abstention	1.050	0,00138044449445%	0,001681722945338%
Blank	0	0,00000000000000%	0,00000000000000%

6. **Adoption, when applicable and within the “Reig Jofre Flexible Dividend” plan, of i) the distribution of dividends against unrestricted reserves and, ii) of an increase in the Company's share capital with a charge to reserves for an amount determined in accordance with the terms of the agreement, through the issuance of new ordinary shares with a nominal value of fifty cents and with provision for incomplete allocation. Offer to shareholders for the purchase of their free allocation rights for a guaranteed price. Request for admission to trading of issued shares. Delegation of powers to the Board of Directors, with express power of substitution, including, among other matters, the power to redraft the article of the Bylaws that regulates the share capital.**

	Shares	% Share Capital	% Share Capital present and/or represented
Affirmative	62.001.593	81,51405495617900%	99,304287233922600%
Against	0	0,000000000000000%	0,000000000000000%
Abstention	1.050	0,00138044449445%	0,001681722945338%
Blank	0	0,000000000000000%	0,000000000000000%

7. **Modification of the article 2 of the Company’s Bylaws, relating to the Company’s corporate purpose, in order to include within the Corporate purpose the provision of marketing and product promotion services.**

	Shares	% Share Capital	% Share Capital present and/or represented
Affirmative	62.001.593	81,51405495617900%	99,304287233922600%
Against	0	0,000000000000000%	0,000000000000000%
Abstention	1.050	0,00138044449445%	0,001681722945338%
Blank	0	0,000000000000000%	0,000000000000000%

8. **Approval of the period of fifteen days for the calling of Extraordinary General Shareholders Meeting in accordance with the article 515 of the Law on Corporations.**

	Shares	% Share Capital	% Share Capital present and/or represented
Affirmative	59.892.914	78,74175560750030%	95,926940701872400%
Against	2.112.465	2,77727683711295%	3,383410344498860%
Abstention	1.050	0,00138044449445%	0,001681722945338%
Blank	0	0,00000000000000%	0,00000000000000%

9. **The delegation of powers to the Board of Directors, with express power of substitution, for the formalization, interpretation, correction and/or implementation of the agreements adopted by the General Shareholders Meeting.**

	Shares	% Share Capital	% Share Capital present and/or represented
Affirmative	62.001.593	81,51405495617900%	99,304287233922600%
Against	0	0,00000000000000%	0,00000000000000%
Abstention	1.050	0,00138044449445%	0,001681722945338%
Blank	0	0,00000000000000%	0,00000000000000%

Yours Faithfully,

Adolf Rousaud
Secretary of the Board of Directors
Laboratorio Reig Jofre, S.A.